A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Inclusion criteria

• - Native Chinese participants must be of an acceptable age to provide informed consent.
• Have measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version 1.1).
• Have disease with evidence of KRAS G12C mutation
• Have a histologically or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and must be appropriate candidates for study treatment.
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Have adequate laboratory parameters.
• Must be able to swallow capsules or tablets.
• Estimated life expectancy ≥12 weeks

Exclusion criteria

• Have disease suitable for local therapy administered with curative intent.
• Have an active fungal, bacterial, and/or active untreated viral infection,
• Have a serious pre-existing medical condition(s) that would preclude participation in this study.
• Have a serious cardiac condition.
• Have untreated active symptomatic central neural system (CNS) malignancy or metastasis and/or carcinomatous meningitis.
• Have received prior treatment with any KRAS G12C small molecule inhibitor.
• Females who are pregnant or lactating.
• Have a known allergic reaction against any of the components of the study drug